LONSURF 15 MG6.14 MG Israel - English - Ministry of Health

lonsurf 15 mg6.14 mg

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

LONSURF 15 MG6.14 MG Israel - English - Ministry of Health

lonsurf 15 mg6.14 mg

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

LONSURF 20 MG8.19 MG Israel - English - Ministry of Health

lonsurf 20 mg8.19 mg

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

LONSURF 20 MG8.19MG Israel - English - Ministry of Health

lonsurf 20 mg8.19mg

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Azacitidine Clonmel 25 mg/ml powder for suspension for injection Ireland - English - HPRA (Health Products Regulatory Authority)

azacitidine clonmel 25 mg/ml powder for suspension for injection

clonmel healthcare ltd - azacitidine - powder for suspension for injection - 25 milligram(s)/millilitre - azacitidine

Azacitidine Rowex 25 mg/ml Powder for suspension for injection Ireland - English - HPRA (Health Products Regulatory Authority)

azacitidine rowex 25 mg/ml powder for suspension for injection

rowex ltd - azacitidine - powder for suspension for injection - 25 milligram(s)/millilitre - azacitidine

DECITABINE S.K Israel - English - Ministry of Health

decitabine s.k

k.s.kim international (sk- pharma) ltd., israel - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - decitabine s.k. is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. decitabine s.k. is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

Azacitidine AqVida 25 mg/ml powder for suspension for injection (100 mg vial) Malta - English - Medicines Authority

azacitidine aqvida 25 mg/ml powder for suspension for injection (100 mg vial)

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Azacitidine AqVida 25 mg/ml powder for suspension for injection (150 mg vial) Malta - English - Medicines Authority

azacitidine aqvida 25 mg/ml powder for suspension for injection (150 mg vial)

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Azacitidine onkovis 25 mg/ml powder for suspension for injection (100 mg vial) Malta - English - Medicines Authority

azacitidine onkovis 25 mg/ml powder for suspension for injection (100 mg vial)

onkovis gmbh grube 45, 82377 penzberg , germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents